by Fahal AH, Ahmed ES, Saeed AA, Fahal LA, Hussein SME, Nakano K, Hata K, Alves F, Nyaoke BA. PLOS Neglected Tropical Diseases 2025, 19(4): e0013000. doi: 10.1371/journal.pntd.0013000
Summary: The authors of this viewpoint discuss the trial of fosravuconazole for the treatment of mycetoma, conducted by the Mycetoma Research Center (MRC) at the University of Khartoum, Sudan, in partnership with DNDi and Eisai. This study is a testament to the power of determination, collaboration, and community engagement in overcoming significant challenges. Despite a backdrop of political instability, the COVID-19 pandemic, and remote and hard-to-reach populations, the MRC successfully navigated its way through the trial with extraordinary resilience and resourcefulness. As well as advancing mycetoma treatment, this study offers invaluable lessons about the importance of investing in neglected disease research, strengthening healthcare infrastructure in endemic regions, and engaging affected communities as partners.
